Mortality, critical illness, and mechanical ventilation among hospitalized patients with COVID-19 on therapeutic anticoagulants.

Anticoagulants COVID-19 Coagulopathy Venous thromboembolism (VTE)

Journal

Thrombosis update
ISSN: 2666-5727
Titre abrégé: Thromb Update
Pays: England
ID NLM: 9918249114406676

Informations de publication

Date de publication:
2021
Historique:
received: 17 10 2020
revised: 06 12 2020
accepted: 08 12 2020
medline: 1 1 2021
pubmed: 1 1 2021
entrez: 15 4 2024
Statut: ppublish

Résumé

COVID-19 is associated with hypercoagulability and increased incidence of thrombosis. We compared the clinical outcomes of adults hospitalized with COVID-19 who were on therapeutic anticoagulants to those on prophylactic anticoagulation. We performed an observational study of adult inpatients' with COVID-19 from March 9 to June 26, 2020. We compared patients who were continued on their outpatient prescribed therapeutic anticoagulation and those who were newly started on therapeutic anticoagulation for COVID-19 (without other indication) to those who were on prophylactic doses. The primary outcome was overall death while secondary outcomes were critical illness (World Health Organization Ordinal Scale for Clinical Improvement score ≥5), mechanical ventilation, and death among patients who first had critical illness. We adjusted for age, sex, race, body mass index (BMI), Charlson score, glucose on admission, and use of antiplatelet agents. Of 1716 inpatients with COVID-19, 171 patients were continued on their therapeutic anticoagulation and 78 were started on new therapeutic anticoagulation for COVID-19. In patients continued on home therapeutic anticoagulation, there were no differences in overall death, critical illness, mechanical ventilation, or death among patients with critical illness compared to patients on prophylactic anticoagulation. In patients receiving new therapeutic anticoagulation for COVID-19, there was increased death (OR 5.93; 95% CI 3.71-9.47), critical illness (OR 14.51; 95% CI 7.43-28.31), need mechanical ventilation (OR 11.22; 95% CI 6.67-18.86), and death after first having critical illness (OR 5.51; 95% CI 2.80-10.87). Therapeutic anticoagulation for inpatients with COVID-19 was not associated with improved outcomes.

Sections du résumé

Background UNASSIGNED
COVID-19 is associated with hypercoagulability and increased incidence of thrombosis. We compared the clinical outcomes of adults hospitalized with COVID-19 who were on therapeutic anticoagulants to those on prophylactic anticoagulation.
Materials and methods UNASSIGNED
We performed an observational study of adult inpatients' with COVID-19 from March 9 to June 26, 2020. We compared patients who were continued on their outpatient prescribed therapeutic anticoagulation and those who were newly started on therapeutic anticoagulation for COVID-19 (without other indication) to those who were on prophylactic doses. The primary outcome was overall death while secondary outcomes were critical illness (World Health Organization Ordinal Scale for Clinical Improvement score ≥5), mechanical ventilation, and death among patients who first had critical illness. We adjusted for age, sex, race, body mass index (BMI), Charlson score, glucose on admission, and use of antiplatelet agents.
Results UNASSIGNED
Of 1716 inpatients with COVID-19, 171 patients were continued on their therapeutic anticoagulation and 78 were started on new therapeutic anticoagulation for COVID-19. In patients continued on home therapeutic anticoagulation, there were no differences in overall death, critical illness, mechanical ventilation, or death among patients with critical illness compared to patients on prophylactic anticoagulation. In patients receiving new therapeutic anticoagulation for COVID-19, there was increased death (OR 5.93; 95% CI 3.71-9.47), critical illness (OR 14.51; 95% CI 7.43-28.31), need mechanical ventilation (OR 11.22; 95% CI 6.67-18.86), and death after first having critical illness (OR 5.51; 95% CI 2.80-10.87).
Conclusions UNASSIGNED
Therapeutic anticoagulation for inpatients with COVID-19 was not associated with improved outcomes.

Identifiants

pubmed: 38620459
doi: 10.1016/j.tru.2020.100027
pii: S2666-5727(20)30027-4
pmc: PMC7732225
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100027

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Niti G Patel (NG)

Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, IL, USA.

Ajay Bhasin (A)

Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, IL, USA.

Joseph M Feinglass (JM)

Northwestern University Feinberg School of Medicine, Division of General Internal Medicine and Geriatrics, Chicago, IL, USA.

Michael P Angarone (MP)

Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, Department of Medicine, Chicago, IL, USA.

Elaine R Cohen (ER)

Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, IL, USA.

Jeffrey H Barsuk (JH)

Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, IL, USA.

Classifications MeSH